new glp 1 drugs 2025 GLP-1 Guidelines for Type 2 Diabetes in glp-1 drugs pharmaceutical companies partnerships
Description
Serious Side Effects: Pancreatitis: Rare (0.18%)
The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
A systematic comparison with other antidiabetic agents reveals notable differences in their influence on cancer risk across drug classes
Thankfully, one oral option is now made in tablet form, with more being developed
They also underscore a strategic imperative: manufacturers must urgently expand capacity to capitalize on the market opportunity, while dealing with supply constraints and time-to-market
